Concepedia

Christine Pien

CP

Statistics

Publications

20

Citations

5.2K

H-Index

18

Active since

1999

Affiliations

Millennium Engineering and Integration (United States)(Current)

Goethe University Frankfurt

Merrimack Pharmaceuticals (United States)

The University of Texas MD Anderson Cancer Center

Harvard University

Christine Pien is an author at Millennium Engineering and Integration (United States) specializing in pharmacology, proteasome inhibitor therapy, and proteasome inhibitors.

Publications per year

1999–2020

20

Publications

20

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Julian Adams, Vito J. Palombella, Edward A. Sausville et al. · PubMed · 1999 · 1.5K citations

, , +14

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 763 citations

, , +17

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Carol Aghajanian, Steven L. Soignet, Don S. Dizon et al. · PubMed · 2002 · 456 citations

, , +14

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Richard LeBlanc, Laurence Catley, Teru Hideshima et al. · PubMed · 2002 · 456 citations

, , +13

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Christos N. Papandreou, Danai Daliani, Darrell Nix et al. · Journal of Clinical Oncology · 2004 · 437 citations · Full text

, , +12

1–5 of 20